Schering Intron-A for hepatitis B saves $6,600 per patient in medical costs, AIM study projects.
Executive Summary
SCHERING's INTRON A SAVES $6,600 PER HEPATITIS B PATIENT v. standard care in lifetime medical costs, according to a cost-effectiveness study of Schering's alpha interferon product published May 1 in the Annals of Internal Medicine. The authors, John Wong, MD, et al., from the New England Medical Center and Tufts University School of Medicine, conducted a meta-analysis of nine randomized controlled clinical trials of Intron A for hepatitis B, projected outcomes based on serological markers used in the trials and modeled costs for standard care versus Intron A therapy. The authors conclude that lifetime costs of standard care would be $60,200 per patient versus $53,600 for Intron A treatment.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth